A regulatory submission is a controlled process with fixed milestones. Every document in the dossier, whether it's a module summary, a labeling package, or a clinical overview, must meet terminology, formatting, and traceability requirements before it reaches the authority.
Managed outside a controlled process, translation becomes a bottleneck: version mismatches, inconsistent terminology, missing review records, or formatting errors requiring rework under deadline pressure.
This article covers what regulatory translation requires, where delays typically originate, and what a controlled translation workflow looks like for submission programs.
Regulatory submission translation requires four controls that go beyond linguistic accuracy: Version alignment between source and translated documents; terminology consistency enforced against an approved term base; documented human review by a qualified specialist; and a retrievable audit trail. These controls are consistent with what major regulatory frameworks expect from submission-grade documentation and are routinely assessed during inspections. If any are absent, the translation process creates submission risk.
What Regulators Require from Translated Submission Content
Regulatory agencies do not specify translation quality in isolation. They expect a documentation system that demonstrates controlled, traceable, and reproducible translation, not just an accurate output.
For submission-grade translation, the baseline requirements are consistent across major regulatory frameworks:
-
Terminological consistency: the same approved term is used across all documents in the dossier and across language versions
-
Version alignment: each translated document corresponds to a specific approved source version, with no undocumented divergence
-
Documented review: a qualified specialist has reviewed and approved the translation, and that review is recorded
-
Audit trail: translation history, versioning, and review records are retrievable to support inspection or authority queries
These requirements apply regardless of whether translation is performed by humans, with AI assistance, or through a combination. The process around translation is what is evaluated, not the method.
Where Translation Delays and Audit Findings Originate
Common causes of translation-related submission delays:
-
Version mismatches: a translated module is based on a source version that was updated after translation began, requiring rework to align with the final approved content
-
Terminology drift: inconsistent use of approved regulatory, clinical, or product terms across documents or language versions, particularly when translation is managed across multiple vendors or freelancers
-
Missing review records: no documented evidence of who reviewed the translation, against which criteria, and when. Inspection readiness requires that this evidence be retrievable on demand.
-
Formatting errors introduced in translation: layout, table structure, or cross-reference numbering altered during linguistic processing, requiring reformatting before submission
-
Late integration: translation treated as a final step rather than a parallel workstream, compressing the review window and increasing the risk of unresolved issues at the deadline
Language and Documentation Requirements by Regulatory Authority
The specific language requirements for regulatory submissions vary by authority, submission type, and market. The table below summarizes the key requirements for major regulatory jurisdictions.
| Regulatory Authority | Language Requirements | Key Translation Controls |
| EMA (EU Centralized) | All 24 EU official languages for approved labeling; submission working language: English | Harmonized terminology across all language versions; version control aligned with approval timeline; traceability from English source to all translated documents |
| National competent authorities (EU decentralized) | Language(s) of the member state(s); requirements vary by procedure type (MRP, DCP) | Consistent application of EMA-aligned terminology where applicable; market-specific formatting requirements |
| FDA (US) | English required for labeling; non-English versions may be required or triggered in defined cases, including foreign-language labeling and patient-facing research materials. | Accuracy and terminological consistency for any non-English labeling or patient-facing materials |
| PMDA (Japan) | Japanese required for official product information and Japan-specific submission components | Official terminology standards; traceability requirements for regulatory-facing documentation |
| NMPA (China) | Chinese required for registration/filing documents and approved labeling/IFU; foreign-language originals may also need to be supplied where translated. | Strict formatting requirements; terminology aligned with locally applicable regulatory standards for device and drug categories |
Note: requirements evolve with regulatory guidance updates: Always verify current requirements with regulatory affairs team and relevant authority guidance documents.
What a Controlled Submission Translation Workflow Includes
A submission-grade translation workflow is not a standard translation project with a compliance label. It requires specific process controls at each stage.
-
Terminology preparation before translation begins: an approved term base covering all critical regulatory, clinical, and product terminology is loaded and enforced before any translation is initiated. Updates to approved terms are version-controlled.
-
Parallel workstream planning: translation is planned as a parallel workstream alongside regulatory writing and review, not as a downstream activity. This prevents the version mismatch scenario that creates the most common rework cycle.
-
AI-assisted drafting with mandatory human review: for high-volume submission content, AI-assisted drafting with terminology enforcement supports throughput management while mandatory expert review by a qualified regulatory linguist covers accuracy, terminological compliance, and regulatory formatting requirements. Review records are documented.
-
Quality gating by document criticality: not all modules in a dossier carry the same risk profile. Clinical overviews, safety summaries, and labeling require the strictest review path. Administrative and non-clinical documentation may follow a lighter but still documented process.
-
Audit trail as a deliverable: the translation record, covering versioned source, translated output, quality score if applicable, reviewer identity, and approval date, is retained with the submission file and accessible for inspection.
How to Evaluate a Translation Partner for Regulatory Submission Work
When evaluating a partner for regulatory submission translation, the following criteria matter more than cost or turnaround time alone.
Regulatory expertise: the partner has direct, documented experience with the specific document types and frameworks relevant to your program (EMA, FDA, PMDA, NMPA, MDR/IVDR), not general life sciences exposure
Terminology governance: the partner maintains a version-controlled term base for your program, enforced at project start, not corrected at review
Documented review process: named qualified reviewers, defined review criteria, and retrievable review records are in place for every submission deliverable, not on request
Version control integration: the partner has a defined process for managing translation updates when source documents change mid-submission cycle, without restarting the full workflow
Audit readiness: the partner can produce complete translation documentation, including version history, reviewer records, and quality data, to support an inspection or authority query
Key Takeaways
-
Regulatory submission translation requires version control, terminology enforcement, documented human review, and a retrievable audit trail, not just accurate output.
-
Most translation-related submission delays originate from version mismatches, terminology drift, and missing review records. All are preventable with a controlled workflow.
-
AI-assisted translation is applicable for high-volume submission content when terminology controls and mandatory expert review are in place.
-
Translation should be planned as a parallel workstream alongside regulatory writing, not as a final step, to protect submission timelines.
-
Evaluate a translation partner on regulatory expertise, terminology governance, review documentation, and audit readiness rather than on speed or price alone.
